TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20511163

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 1 (arm A)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Weight-based, dose-adjusted filgrastim beginning on day 1 (arm B)
Number of subjects: 101
Study: 17009304

Group type: EXPERIMENTAL
Intervention: 0.3 M potassium chloride (KCl)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 23
Study: 17110817

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/d
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Quetiapine (both doses)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 15279057

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS (Control)
Number of subjects: 22
Study: 11077496

Group type: EXPERIMENTAL
Intervention: ppWhipple
Number of subjects: 93

Group type: COMPARATOR
Intervention: cWhipple
Number of subjects: 93
Study: 8739501

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate eyedrops
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate eyedrops
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0% sodium hyaluronate eyedrops
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.05% sodium hyaluronate eyedrops
Number of subjects: 12
Study: 1404632

Group type: EXPERIMENTAL
Intervention: Papaverine plus prostaglandin E1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Papaverine plus phentolamine plus prostaglandin E1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Papaverine plus phentolamine
Number of subjects: 7
Study: 2408846

Group type: EXPERIMENTAL
Intervention: Clonidine (225 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine + Yohimbine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30113524

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 1514

Group type: COMPARATOR
Intervention: National guidelines for physical activity (Control)
Number of subjects: 1514
Study: 27956057

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05μg/kg/min (group R1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1μg/kg/min (group R2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High levels of anxiety
Number of subjects: 60
Study: 25586812

Group type: EXPERIMENTAL
Intervention: Home telemonitoring with usual care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 23499726

Group type: EXPERIMENTAL
Intervention: Octreotide-evorolimus combination therapy (everolimus 2.5 mg daily + octreotide 40 mg every 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Octreotide monotherapy (octreotide 40 mg every 4 weeks)
Number of subjects: 44
Study: 21459996

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Counseling or psychotherapy
Number of subjects: 206
Study: 18095028

Group type: EXPERIMENTAL
Intervention: Topical sucralfate cream
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 116
Study: 16426710

Group type: EXPERIMENTAL
Intervention: Polyphenol supplement (2.3g polyphenols/trial)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14594754

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nutritional counseling
Number of subjects: 33
Study: 11069364

Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma‐1b (60 microg/m2) subcutaneously once every 7 days until disease progression
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study: 8616014

Group type: EXPERIMENTAL
Intervention: FLAC + PIXY321
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLAC + GM‐CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: FLAC without cytokine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three treatment arms (FLAC + PIXY321, FLAC + GM‐CSF, FLAC without cytokine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLAC
Number of subjects: 0
Study: 1330271

Group type: EXPERIMENTAL
Intervention: Afternoon testing (5.0 W.kg‐1 for women, 6.0 W.kg‐1 for men)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Morning testing (5.0 W.kg‐1 for women, 6.0 W.kg‐1 for men)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Afternoon testing
Number of subjects: 14
Study: 3965024

Group type: EXPERIMENTAL
Intervention: Modified fat diet (rich in linoleic acid)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Low carbohydrate diet
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Low linoleic acid levels
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: High linoleic acid levels
Number of subjects: 149
Study: 30626414

Group type: EXPERIMENTAL
Intervention: TRT + EMDR
Number of subjects: 166

Group type: COMPARATOR
Intervention: TRT + CBT
Number of subjects: 166
Study: 30249826

Group type: EXPERIMENTAL
Intervention: AT‐TORBI plate haptic toric IOL
Number of subjects: 42

Group type: COMPARATOR
Intervention: AcrySof loop haptic toric IOL
Number of subjects: 42
Study: 26836730

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500-1000 mg, twice daily)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 25181492

Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: High fibre cereal breakfast
Number of subjects: 4116

Group type: COMPARATOR
Intervention: Not usually having breakfast
Number of subjects: 4116
Study: 22112608

Group type: EXPERIMENTAL
Intervention: Aflibercept 4mg/kg every 2 weeks
Number of subjects: 16
Study: 19453849

Group type: EXPERIMENTAL
Intervention: Particulate demineralized bone matrix (DBM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Putty demineralized bone matrix (DBM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 25
Study: 17215188

Group type: EXPERIMENTAL
Intervention: NaFeEDTA (20 mg Fe/kg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FeSO4 (30 mg Fe/kg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Elemental iron (60 mg Fe/kg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no added iron)
Number of subjects: 400
Study: 15285975

Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 119

Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 119
Study: 11730828

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (2 mg of estradiol combined with 1 mg of norethisterone acetate daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 9143862

Group type: EXPERIMENTAL
Intervention: Celiprolol (2 times 0.5 mg.kg‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study: 8233423

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 3440102

Group type: EXPERIMENTAL
Intervention: Adenosine after placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enprofylline
Number of subjects: 10
Study: 31939259

Group type: EXPERIMENTAL
Intervention: Freshwater snails identified and their geographical distribution determined using multistage sampling and ArcGIS software.
Number of subjects: 4400
Study: 28189500

Group type: EXPERIMENTAL
Intervention: Shaping Healthy Choices Program (SHCP)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 409
Study: 26752189

Group type: EXPERIMENTAL
Intervention: Mericitabine added to PI plus PegIFN alfa‐2a/RBV therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer treatment with mericitabine (24 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telaprevir-containing regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens that included 48 weeks of PegIFN alfa‐2a/RBV therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mericitabine
Number of subjects: 0
Study: 25141831

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA-Supreme
Number of subjects: 100
Study: 21805567

Group type: EXPERIMENTAL
Intervention: 4 Fr catheters with ACI
Number of subjects: 164

Group type: COMPARATOR
Intervention: 6 Fr catheters with manual injection
Number of subjects: 164
Study: 18626783

Group type: EXPERIMENTAL
Intervention: Transperineal urethrosphincteric block (TUSB) using 10‐20 ml of 1% lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intraurethral 30 ml of 2% lidocaine jelly
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intraurethral 30 ml of neutral jelly
Number of subjects: 150
Study: 17988462

Group type: EXPERIMENTAL
Intervention: Hydrolysis with Escherichia coli beta‐glucuronidase followed by 10N NaOH; urine samples adjusted to pH 5-6.5, treated with acetonitrile, and quantified by gas chromatography-mass spectrometry.
Number of subjects: 0
Study: 16230677

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with oxaliplatin 70 mg/m2 weekly for six doses
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 115
Study: 11955392

Group type: EXPERIMENTAL
Intervention: 0.3 IU/kg/day recombinant human growth hormone (rhGH) from postoperative day 1 to day 10
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.3 IU/kg/day recombinant human growth hormone (rhGH)
Number of subjects: 50
Study: 10507268

Group type: EXPERIMENTAL
Intervention: 30‐second inhalations of methacholine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2‐minute inhalations of methacholine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of 2‐minute PC20 multiplied by 4 and 30‐second PC20
Number of subjects: 10
Study: 8565538

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg/hr rhIL-1ra
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg/hr rhIL-1ra
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: rhIL-1ra (both dosages)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study: 1827013

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 20
Study: 6282460

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Maytansine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Chlorozotocin
Number of subjects: 73
Study: 31102438

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 31
Study: 28948420

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26264425

Group type: COMPARATOR
Intervention: Strength Training + Placebo (ST + placebo)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Strength Training + Testosterone Treatment (ST + TT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Testosterone Treatment (TT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24119807

Group type: COMPARATOR
Intervention: Humulin‐N (H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin glargine (L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 21598491

Group type: EXPERIMENTAL
Intervention: Dual-cured resin combined with dentin pin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dual-cured resin (control group)
Number of subjects: 38
Study: 19411792

Group type: EXPERIMENTAL
Intervention: Health education program using problem-based learning, 5 weekly sessions, 100-120 min/session
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no health education program)
Number of subjects: 44
Study: 18060072

Group type: EXPERIMENTAL
Intervention: Virosomal formulations of UK-39 (10 microg dose)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Co-administration of UK-39 and AMA49-C1 loaded virosomes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Purified total IgG from UK-39 immunized volunteers
Number of subjects: 46

Group type: COMPARATOR
Intervention: Empty virosomes
Number of subjects: 46
Study: 15606400

Group type: EXPERIMENTAL
Intervention: Gastro-oesophageal reflux disease subjects
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 83
Study: 11023168

Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg/kg/min, increased every 20 min by 2.5 microg/kg/min up to 10 microg/kg/min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg/min, increased every 20 min by 2.5 microg/kg/min up to 10 microg/kg/min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Change from dobutamine to dopamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Change from dopamine to dobutamine
Number of subjects: 66
Study: 9059563

Group type: EXPERIMENTAL
Intervention: Pamidronate therapy (150 mg/day) for 3 years
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Discontinuation of pamidronate therapy for 12 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Post-discontinuation BMD measurement after 1 year
Number of subjects: 22
Study: 1347659

Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4054700

Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: L-dopa (100 mg) plus carbidopa (35 mg) after pretreatment with carbidopa (50 mg every six hours for four doses)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3678161

Group type: EXPERIMENTAL
Intervention: Meglumine/Sodium Ioxaglate (Hexabrix 320)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Meglumine/Sodium Diatrizoate (Urografin 310)
Number of subjects: 94
Study: 31721153

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 399

Group type: COMPARATOR
Intervention: PORT
Number of subjects: 399
Study: 30537937

Group type: EXPERIMENTAL
Intervention: BEATVIC therapy (body-oriented resilience therapy using kickboxing exercises)
Number of subjects: 24
Study: 25742631

Group type: EXPERIMENTAL
Intervention: Low pressure (<15 psi)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High pressure (>20 psi)
Number of subjects: 9
Study: 23065684

Group type: EXPERIMENTAL
Intervention: Risk of Ovarian Cancer Algorithm (ROCA)
Number of subjects: 251
Study: 20039959

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 18398147

Group type: EXPERIMENTAL
Intervention: Toremifene (80 mg/d)
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1389
Study: 16608025

Group type: EXPERIMENTAL
Intervention: Gum-chewing (three times a day after operation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no gum-chewing)
Number of subjects: 22
Study: 15071266

Group type: EXPERIMENTAL
Intervention: Pacing with rate drop sensing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sensing without pacing (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pacing (overall)
Number of subjects: 100
Study: 11082523

Group type: EXPERIMENTAL
Intervention: Bilateral resin-bonded bridges
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower partial denture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prosthetic rehabilitation (both interventions)
Number of subjects: 40
Study: 9384340

Group type: EXPERIMENTAL
Intervention: Pnc-D (tetravalent pneumococcal vaccine conjugated to diphtheria toxoid)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pnc-T (tetravalent pneumococcal vaccine conjugated to tetanus toxoid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1543819

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg am
Number of subjects: 264

Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte
Number of subjects: 264
Study: 3159324

Group type: EXPERIMENTAL
Intervention: Mass closure (all layers except skin)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Layered closure (anterior and posterior aponeuroses separately sutured)
Number of subjects: 282
Study: 30657251

Group type: EXPERIMENTAL
Intervention: Coaxial tubular superelastic NiTi
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-stranded superelastic NiTi
Number of subjects: 40
Study: 29763709

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 27028957

Group type: EXPERIMENTAL
Intervention: Somatostatin analog (SSA) therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no SSA therapy)
Number of subjects: 36
Study: 23640652

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy regimen
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline measures of UAI
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Socio-demographic factors (Latino ethnicity)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (crystal methamphetamine use, greater life stress, lower trait anxiety)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Problem drinking
Number of subjects: 134
Study: 23681906

Group type: EXPERIMENTAL
Intervention: Inhaled dual release ciprofloxacin (DRCFI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20492710

Group type: EXPERIMENTAL
Intervention: Gold+Lutein (Wyeth S‐26 Gold fortified with lutein at 200 mcg/l)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Gold (Wyeth S‐26 Gold, control formula)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 232
Study: 19102266

Group type: EXPERIMENTAL
Intervention: Nutritional support increased intravenously for 14 days (7 days before and after operation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine diet (Control group)
Number of subjects: 48
Study: 17277679

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 286
Study: 12580941

Group type: EXPERIMENTAL
Intervention: 0.8 IU GH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2.0 IU GH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 21 IU GH
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2 IU GH
Number of subjects: 26
Study: 10849523

Group type: EXPERIMENTAL
Intervention: Roquinimex 0.2 mg/kg body weight, twice weekly for 2 years
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 9203426

Group type: EXPERIMENTAL
Intervention: Higher-dose amphotericin B (0.7 mg/kg/day) plus flucytosine (100 mg/kg/day) for two weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Higher-dose amphotericin B (0.7 mg/kg/day) alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day) for eight weeks
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg/day) for eight weeks
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 202
Study: 1313104

Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrice (standard abrasivity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate dentifrice (low abrasivity)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 3697596

Group type: EXPERIMENTAL
Intervention: TLC prone (tank) method
Number of subjects: 80

Group type: COMPARATOR
Intervention: RV seated (pool) method
Number of subjects: 80
Study: 31339000

Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF) from 8 am to 2 pm
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control schedule (eating from 8 am to 8 pm)
Number of subjects: 11
Study: 29402752

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d for 3 years or until recurrence)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 26322788

Group type: EXPERIMENTAL
Intervention: Vets Prevail online cognitive-behavioral therapy intervention
Number of subjects: 303

Group type: COMPARATOR
Intervention: Adjustment as usual (control)
Number of subjects: 303
Study: 25704335

Group type: EXPERIMENTAL
Intervention: Collaborative intervention to support unmarried coparents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23489232

Group type: EXPERIMENTAL
Intervention: 8% arginine and 1,450 ppm sodium monofluorophosphate dentifrice
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate and 1,040 ppm sodium fluoride dentifrice
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 30% microaggregation of zinc‐carbonate hydroxyapatite nanocrystals dentifrice
Number of subjects: 85
Study: 20845628

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg-1 intravenously 20 min before completion of surgery
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76
Study: 19014842

Group type: EXPERIMENTAL
Intervention: Cefditoren (8-12 mg/kg daily) for 14 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (80-90 mg/kg amoxicillin daily) for 14 days
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cefditoren
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 142